On the effect of chelating agents and antioxidants on cadmium-induced organ toxicity. An overview by Ivanova, Juliana et al.
European	Journal	of	Chemistry	4	(1)	(2013)	74‐84	
European	Journal	of	Chemistry	
ISSN	2153‐2249	(Print)	/	ISSN	2153‐2257	(Online)		2013	EURJCHEM	
DOI:10.5155/eurjchem.4.1.74‐84.739	
	
	
	
	
European	Journal	of	Chemistry	
Journal	homepage:	www.eurjchem.com	
	 	 	
On	the	effect	of	chelating	agents	and	antioxidants	on	cadmium‐induced	organ	
toxicity.	An	overview	
Juliana	Ivanova	a,*,	Yordanka	Gluhcheva	b,	Denitsa	Tsanova	a,	Angelina	Piskova	a,	Radostina	Djaleva	a,	
Steliana	Mokresheva	a,	Dimitrina	Kamenova	a,	and	Mariana	Mitewa	c	
a	Faculty	of	Medicine,	Sofia	University	“St.	Kl.	Ohridski”,	1407	Sofia,	Bulgaria	
b	Institute	of	Experimental	Morphology,	Pathology	and	Anthropology	with	Museum,	BAS,	1113,	Sofia,	Bulgaria	
c	Faculty	of	Chemistry	and	Pharmacy,	Sofia	University,	“St.	Kl.	Ohridski”,	1164	Sofia,	Bulgaria	
*Corresponding	author	at:	Faculty	of	Medicine,	Sofia	University	“St.	Kl.	Ohridski”,	1407	Sofia,	Bulgaria.		
Tel.:	+359.2.8161247;	fax:	+359.2.9625438.	E‐mail	address:	dkji@chem.uni‐sofia.bg	(J.	Ivanova).	
	
	
	 	
	 	 	
REVIEW	INFORMATION	 	 ABSTRACT
Received:	31	January	2013	
Accepted:	16	February	2013	
Online:	31	March	2013	
KEYWORDS	
	 Cadmium	 (Cd)	 has	 been	 classified	 as	 a	 human	 carcinogen.	 The	World	 Health	 Organization
(WHO)	reported	that	the	concentration	of	Cd	in	the	environment	has	rapidly	increased	in	the
last	 few	 years.	 In	 many	 epidemiological	 studies,	 the	 correlation	 between	 environmental
exposure	 of	 humans	 to	 Cd	 and	 diseases	 such	 as	 stroke,	 ischemia,	 renal	 and	 hepatic
dysfunction,	 anemia,	 osteoporosis	 and	 diabetes	 has	 been	 discussed.	 For	 the	 treatment	 of
heavy	metal	intoxications	a	therapy	with	chelating	agents	has	been	applied.	A	chelating	agent
is	 a	 compound	 that	 binds	 the	 toxic	 metal	 ion	 thus	 promoting	 its	 excretion	 by	 the	 living
organisms.	 Recently,	 it	 has	 been	 found	 that	 Cd‐induced	 toxicity	 is	 a	 result	 of	 formation	 of
reactive	oxygen	species	(ROS).	These	results	increased	the	interest	towards	the	antioxidants
as	 possible	 agents	 for	 the	 treatment	 of	 Cd‐induced	 organ	 toxicity.	 Herein,	 we	 present
summary	 and	 discussion	 of	 the	 literature	 data	 for	 the	 influence	 of	 chelating	 agents	 and
antioxidants	on	Cd‐induced	pathological	conditions	in	Cd‐intoxicated	animals.	
Vitamins	
Cadmium	
Toxicology	
Ionophores	
Antioxidants	
Medicinal	chemistry	
	
1.	Introduction	
	
Cadmium	 (Cd)	 is	 a	 toxicant,	 classified	 as	 a	 human	
carcinogen	by	the	International	Agency	for	Research	on	Cancer	
[1].	According	 to	 the	data	provided	by	 the	WHO,	 the	daily	Cd	
intake	 varies	 in	 the	 interval	 from	 40	 μg	 (for	 people	 living	 in	
unpolluted	regions)	to	200	μg	(for	people	from	polluted	areas)	
[2,3].	The	level	at	which	chronic	exposure	to	Cd	is	not	likely	to	
cause	cancer	or	adverse	health	effects	is	14	μg	per	day	[2,3].	Cd	
is	a	very	dangerous	environmental	pollutant	due	to	its	ability	to	
cause	 severe	 organ	 toxicity.	When	 accumulated	 in	 the	body	 it	
induces	hepatotoxicity	[4],	renal	dysfunction	[5,6],	distortion	of	
the	 reproductive	 function	 [7,8]	 and	 cardiovascular	 injury	 [9‐
14].	
Compounds	that	possess	low	toxicity,	good	absorbability	by	
the	 gastrointestinal	 tract	 and	bind	 toxic	metal	 ions	have	been	
used	 in	 the	chelation	 therapy	 for	 the	 treatment	of	 toxic	metal	
intoxication	[15‐17].	Many	chelating	agents	have	been	tested	to	
mobilize	Cd	but	no	effective	chelation	therapy	is	available	so	far	
for	humans,	exposed	to	Cd	intoxication	[18].		
It	has	been	discussed	that	the	oxidative	stress	is	one	of	the	
mechanisms	for	the	Cd‐induced	toxicity	[19‐21].	Albeit	Cd	does	
not	generate	free	radicals	by	itself	it	replaces	the	iron	(Fe)	and	
copper	 (Cu)	 from	 cytoplasmic	 proteins	 and	 metalloenzymes	
[19].	 Free	 iron	 and	 copper	 ions	 participate	 in	 Fenton	 type	
reactions	 leading	 to	 the	 generation	 of	 ROS	 [19‐21].	 Other	
possible	 mechanism	 for	 Cd‐induced	 oxidative	 stress	 includes	
direct	interaction	of	Cd	with	SH	groups	of	the	thiols	[20,21].	In	
the	 last	 years	 enormous	data	 regarding	 the	 application	of	 the	
antioxidants	for	the	treatment	of	Cd‐induced	toxicity	have	been	
published	[3].	
Herein	 we	 present	 a	 summary	 of	 the	 antioxidants	 and	
chelating	 agents	 screened	 on	 animal	 models	 to	 decrease	 Cd	
concentrations	in	the	body	and	to	prevent	Cd‐induced	oxidative	
stress.	The	data	presented	 in	 this	 review	comprise	 the	period	
1992‐2012	years.	Discussion	of	the	antioxidants	and	chelating	
agent	 tested	 to	 inhibit	 Cd‐induced	 hepatotoxicity,	 renal	
dysfunction,	 testicular	 toxicity	 and	 cardiac	 impairment	 is	
provided.	
	
2.	Effect	of	antioxidants	and	chelating	agents	on	Cd‐
induced	hepatotoxicity	
	
The	 liver	 and	 kidneys	 are	 critical	 organs	 in	 Cd‐induced	
intoxications.	 When	 accumulated	 in	 the	 liver	 Cd	 induces	
inflammatory	 cell	 infiltrations,	 dilation	 of	 sinosoids	 and	
disorganization	 of	 the	 normal	 radiating	 pattern	 of	 the	
hepatocytes	around	the	central	vein	[22‐24].	At	acute	and	long‐
lasting	chronic	Cd‐intoxications	necrosis	of	 the	central	vein	of	
the	liver	has	been	observed	[22].		
	
2.1.	Antioxidants,	tested	on	animal	models	for	the	treatment	
of	Cd‐induced	hepatotoxicity	
	
The	 antioxidants	 tested	 on	 animal	models	 to	 prevent	 Cd‐
induced	 hepatotoxicity	 are	 presented	 in	 Tables	 1	 and	 2.	 As	
could	be	seen	from	the	data,	presented	in	both	tables,	 there	is	
an	 enormous	 diversity	 of	 experimental	 models,	 published	 by	
authors	of	studies	dealing	with	the	effect	of	the	antioxidants	on	
Cd‐induced	hepatotoxicity.		
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Table	1.	Antioxidants,	tested	on	animal	models	for	the	treatment	of	Cd‐induced	hepatotoxicity,	caused	by	acute	and	subacute	Cd‐exposure.	
Antioxidant	 Route	of	
administration	
Dose	and	duration	of	
administration	
Animal	model	 Effect	 Ref.	
Alpha	lipoic	acid	
(α‐LA)	
i.p.	 LA:Cd	=	5:1.	The	
antioxidant	is	co‐
administrated	with	Cd(II)	
salt	
Male	mice,	acute	intoxicated	
with	40	μmol/kg	Cd(II)	salt	
(s.c.)	
Cd	accumulation	is	not	affected	by	LA.	The	
antioxidant	does	not	recover	the	activity	of	CAT	
and	GSH	level,	but	the	mortality	associated	with	
Cd‐intoxication	is	decreased	by	LA.	
[25]	
Curcumin	 p.o.	 50	mg/kg	b.w.,	applied	
before	Cd‐intoxication	for	
3	days	
Male	mice	and	male	rats,	
acute	intoxicated	with	0,025	
and	0,03	mmol/kg	b.w.	
Cd(II)	chloride	(s.c.)	
LPO	is	abolished	by	the	antioxidant,	but	Cd‐
induced	GSH	depletion	in	the	mice	liver	is	not	
significantly	affected.	Cd	concentration	and	trace	
elements	homeostasis	are	not	changed	by	the	
antioxidant.	
[26]
Curcumin	and	Mn‐
curcumin	complex	
p.o.	 0,14	mmol/kg	b.w,	
applied	for	3	days	before	
intoxication	
Male	mice,	intoxicated	s.c.	
with	33	μmol/kg	Cd(II)	
chloride	
Both	compounds	prevent	Cd‐induced	decrease	of	
GSH	but	do	not	affect	Cd	accumulation.	The	
treatment	with	Mn	complexes	causes	an	increase	
of	Fe	and	Mn	in	the	kidneys	in	the	control	and	Cd‐
treated	mice	and	Fe	and	Cu	in	the	brain	of	the	
control	mice.		
[27]
Curcumin,	
resveratol,	
melatonin	
p.o.	 50	mg/kg	b.w.	curcumin;	
20	mg/kg	b.w	‐	
resveratrol;	melatonin	‐	
12	mg/kg,	dispersed	in	
0.5%	methylcellulose.	
Duration	‐	3	days	
Male	mice,	intoxicated	with	
Cd(II)	chloride	(7	mg/kg	
b.w.,	s.c.)	
The	Cd‐induced	decrease	of	GSH	level	in	the	liver	
is	not	prevented	by	the	antioxidants.	Resveratol	
recovers	CAT	activity.The	MDA	and	GPx	level	is	
returned	to	normal	in	the	pretreated	animals.	The	
antioxidants	do	not	affect	Cd	accumulation.	
[28]
Vitamin	E	 Information	not	
found	
100	mg/kg,	applied	before	
intoxication	
Male	rats,	intoxicated	i.v.	
with	2	mg/kg	Cd	(II)	
Vit.	E	improves	SOD	and	CAT	activity	in	the	liver	
as	well	as	GSH	level.	The	antioxidant	has	been	
shown	to	recover	Hb	and	HCT	in	the	blood.	
[32]	
Diallyl	tetrasulfide	
(DTS)	
p.o.		 40	mg/kg	(optimum	dose)	
for	3	weeks,	applied	
together	with	Cd(II)	
Male	rats,	intoxicated	with	3	
mg/kg	Cd(II)	s.c.	for	3	weeks	
DTS	significantly	reduces	the	accumulation	of	Cd	
and	restores	the	levels	of	the	antioxidant	defense	
in	the	liver.	DTS	improves	the	hepatocytes	
morphology.	
[29,	30]	
Endomorophin	1	
(EM1)	
i.p.		 50	μM	/kg	per	day	for	6	
days	‐	optimum	dose.	The	
antioxidant	has	been	
coadministrated	with	Cd	
(II)	
Male	mice,	injected	i.p.	with	
Cd(II)	chloride	(1	mg/kg	per	
day)	for	6	days	
EM1	reduces	the	Cd	accumulation	up	to	28	%	
compared	to	the	toxic	control.	EM1	attenuates	Cd‐
induced	alterations	in	MDA	levels,	GSH,	SOD,	and	
CAT	but	MDA	values	remain	higher	than	the	
controls.	On	the	morphological	level,	the	
degenerative	changes	are	reduced	by	EM1.	
[31]
Taurine	 p.o.	 150	mg/kg	body	weight,	
once	daily	for	5	days	prior	
Cd‐intoxication	
Mice	received	Cd	(II)	
chloride	orally	through	
drinking	water	at	a	dose	of	4	
mg/kg	b.w.	for	6	days,	once	
daily	
Taurine	significantly	increases	SOD	and	CAT	
activity	but	at	optimum	dose	the	values	remains	
15%	and	20%	lower	than	the	controls.	Taurine	
prevents	Cd	accumulation	by	50%	and	preserves	
the	homeostasis	of	the	trace	elements.	
Considerable	improvement	of	the	liver	
morphology	by	the	antioxidant	is	observed.	
[22]	
Panax	ginseng	(Pg)	 p.o.	 10	mg/kg	
b.	w.	for	10	days	prior	to	
Cd‐intoxication	and	
continued	up	to	30	days	
after	Cd(II)	chloride	
administration	
Male	mice,	acute	intoxicated	
with	Cd(II)	chloride	(1	
mg/kg	b.	w.,	i.p.	once)	
The	antioxidant	recovers	GSH	and	ALP.	TBARS	is	
partly	affected	by	Pg.	TBARS	levels	remain	higher	
than	the	control	(about	20	%).	
[34]
Carnosine	 i.p.	 10	mg/kg/day	is	applied	
for	three	consecutive	
days,	starting	one	day	
before	Cd‐	
administration	
Male	mice,	acute	intoxicated	
with	6.5	mg/kg	Cd(II)	
chloride	i.p.	
The	antioxidant	partly	reduces	MDA,	and	
increases	GSH,	CAT	and	SOD.	CAT,	SOD	and	GSH	
remain	lower	with	15	%,	20	%,	and	10	%	
respectively	than	the	controls.	Carnosine	
decreased	by	87%	Cd	concentration	and	
recovered	Zn	homeostasis.	On	the	morphological	
level	a	significant	improvement	of	the	radiating	
hepatocytes	structure	is	observed	in	carnosine	
treated	mice.	
[23]	
Solublequercetin‐
50‐sulfonic	acid	
sodiumsalt	
(NaQSA);	
andmorin‐50‐
sulfonic	acid	
sodium	salt	
(NaMSA)	
i.p.	 20	mg/kg	b.w.	after	Cd‐
intoxication	
10	mg/kg	in	combination	
of	both	flavanoids	
Male	mice,	intoxicated	with	
0.64	mg/kg	b.w	Cd(II)	
chloride	s.c.	
Both	antioxidants	increased	the	level	of	SOD	and	
GSH,	but	the	values	remained	lower	than	the	
controls	(30	%	and	20	%	respectively).	
[35]	
Garlic	and	Ascorbic	
acid	
p.o.	 100	mg/kg,	pretreated	for	
4	weeks	
Male	rats	‐ acute	intoxicated	
with	Cd	(II)	chloride	4	
mg/kg	b.w.	
(	i.p.).	
The	antioxidants	recover	SOD	and	CAT	activity	
and	return	to	normal	the	LPO	level.	
[33]
	
	
In	most	papers,	however,	 the	effect	of	 the	antioxidants	on	
Cd‐induced	 oxidative	 stress	 in	 the	 liver	 is	 monitored	 by	 the	
analysis	 of	 superoxide	 dismutase	 activity	 (SOD),	 catalase	
activity	 (CAT),	 gluthathione	 level	 (GSH)	 and	 level	 of	 lipid	
peroxidation	 (LPO),	 expressed	 as	 thiobarbituric	 acid	 reactive	
species	(TBRAS)	or	malondyaldehyde	(MDA).	Cd	decreases	the	
level	of	GSH,	and	the	activity	of	SOD	and	CAT	in	the	liver	of	Cd‐
intoxicated	 animals	 and	 induces	 a	 significant	 increase	 of	LPO.	
All	antioxidants	studied	have	been	demonstrated	to	prevent	in	
some	 extent	 Cd‐induced	 oxidative	 stress	 in	 the	 liver	 of	 Cd‐
treated	animals.		
	
2.1.1.	Effect	of	antioxidants	on	Cd‐induced	hepatoxicity	in	
animals,	subjected	to	acute	and	subacute	Cd‐intoxications		
	
The	 antioxidants,	 screened	 on	 animal	 models	 for	 the	
treatment	 of	 Cd‐induced	 hepatotoxicity,	 caused	 by	 acute	 and	
subacute	Cd‐exposure,	are	presented	on	Table	1.	
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Table	2.	Antioxidants,	tested	on	animal	models	for	the	treatment	of	Cd‐induced	hepatotoxicity	in	subchronic	and	chronic	Cd‐intoxications.		
Antioxidant	 Route	of	
administration	
Dose	 Animal	model	 Effect	 Ref.	
Hydroxytyrosol,	
(DPE)	
Information	not	
found	
9	mg/kg,	applied	after	
Cd‐intoxication	
Male	rats DPE	inhibits	Cd‐induced	toxicity	in	the	liver	 [42]
Diphenyl	diselenide	
((PhSe)2)	
s.c.	 5	μmol/kg	 Male	mice,	subchronically	
intoxicated	with	10	μmol	
Cd(II)	salt	five	times	per	
week	for	four	weeks		
The	antioxidant	restores	the	activity	of	AST	and	TBARS	
to	normal	values.	Diphenyl	diselenide	decreases	ALT	
activity	in	the	plasma	of	Cd‐treated	mice	but	the	value	
remains	higher	than	the	controls	(70	%).	The	effect	of	
the	antioxidant	on	the	Cd	and	trace	elements	level	is	
not	studied.	
[36]	
Melatonin	 p.o		 4	μg/mL	for	8	weeks	
applied	together	with	
Cd(II)	
Female	and	male	mice,	
subchronically	intoxicated	
with	50	μg	Cd/mL	as	Cd(II)	
chloride	for	8	weeks	
Melatonin	decreases	Cd	level	by	24	%	compared	to	the	
toxic	control;	the	antioxidant	however	decreases	
hepatic	iron	to	14%	compared	to	the	toxic	control.	Cd	
diminishes	Fe	level	to	20	%	compared	to	the	control;	
TBRAS	levels	are	recovered	by	the	antioxidant	and	are	
even	lower	than	the	normal	control.	
[38]
Hibiscus	sabdariffa	
L	petal	
Information	not	
found	
Applied	before	
intoxication	
Male	rats,	chronically	
intoxicated	with	Cd(II)	
The	antioxidant	decreases	the	levels	of	AST	and	ALT	in	
the	blood	plasma.	
[43]	
Diphenyl	diselenide,	
(PhSe)2	
p.o.	 5	μmol/kg,	applied	
together	with	Cd(II)	
administration	for	30	
days	
Male	rats,	orally	intoxicated	
with	10	μmol/kg	Cd(II)	
chloride	for	30	days	
The	antioxidant	reduces	the	levels	of	the	hepatic	
enzymes;	MDA,	urea	and	bilirubin.	
[36]
Hesperetin	(HTN)	 p.o.	in	0.1%	
carboxymethyl	
cellulose	
40	mg/kg/day	for	21	
days	
Male	rats,	intoxicated	s.c.	for	
21	days	with	3	mg/kg	b.w.	
Cd	(II)	chloride		
Hesperetin	increases	SOD	and	CAT	levels	but	the	
values	remain	lower	than	the	controls	‐	30	and	15%	
respectively.	The	hepatic	enzymes	were	partially	
recovered.	TBARS	are	affected	by	HTN	but	the	values	
remain	higher	than	the	control	(30	%).	Normal	hepatic	
architectural	pattern	with	mild	dilation	of	sinusoids	in	
Cd+HTN	treated	animals	was	observed.	
[24]
Organo‐
selenocyanates	
p.o.	 3	mg/kg	for	20	days	
applied	concomitant	or	
prior	to	Cd‐intoxication.	
Female	mice,	intoxicated	i.p.	
with	2	mg/kg	Cd(II)	chloride	
for	20	days	
The	tested	compounds	do	not	correct	SOD	level.	GSH	is	
completely	recovered	by	the	antioxidants,	CAT	‐	
partially	(values	remain	10	%	lower	than	the	controls).	
TBARS	level	is	20	%	higher	compared	to	the	controls	in	
the	Cd+antioxidant	treated	mice.	The	antioxidants	
recover	partially	the	hepatic	enzymes.	Normal	central	
vein	and	hepatocytes	structure	in	antioxidant‐treated	
animals	is	observed.		
[39]
Naringenin	(NGN)	 p.o.	 50	mg/kg	for	4	weeks,	
administrated	together	
with	Cd(II)	
Male	rats,	orally	intoxicated	
with	Cd(II)	(5mg/kg)	for	4	
weeks	
NGN	recovers	the	levels	of	the	hepatic	and	antioxidant	
enzymes	near	to	their	normal	values	and	preserves	the	
normal	histological	architecture.	
[40]	
Naringenin+Vitamin	
C+VitaminE	
p.o.		 50	mg/kg	for	28	days	of	
each	compound,	
administrated	together	
with	Cd(II)	
Male	rats,	intoxicated	orally	
with	Cd(II)	chloride	5	mg/kg	
b.w.	for	28	days	
The	combination	of	three	antioxidant	results	in	
complete	recovery	of	SOD,	CAT,	GSH,	TBARS	and	the	
hepatic	enzymes.	Normal	hepatic	architecture	is	
observed	in	the	animals	treated	with	the	three	
antioxidants.	
[41]
	
	
	
Among	 the	 antioxidants,	 presented	 in	 the	 Table	 1,	 alpha	
lipoic	acid	(α‐LA),	curcumin,	Mn‐curcumin	complex,	resveratol	
and	 melatonin	 have	 been	 shown	 not	 to	 prevent	 Cd‐
accumulation	in	the	liver	of	Cd‐treated	animals	[25‐28].		
Alpha	 lipoic	 acid	 (α‐LA),	 resveratol	 and	melatonin	did	not	
affect	Cd‐induced	decrease	of	GSH	level	in	the	liver,	suggesting	
that	 these	 antioxidants	 might	 not	 be	 the	 best	 choice	 for	 the	
treatment	of	Cd‐induced	oxidative	stress	in	the	liver	of	animals,	
subjected	 to	 subacute	 and	 acute	Cd‐intoxications	 [25,28].	Mn‐
curcumin	complex	recovers	GSH	level	in	the	liver	but	the	effect	
of	this	antioxidant	on	the	trace	element	homeostasis	especially	
Fe	 and	 Cu	 should	 be	 taken	 into	 account	 when	 Mn‐curcumin	
complex	is	applied	for	the	therapy	of	Cd‐induced	hepatotoxicity	
[27].		
Diallyl	 tetrasulfide	 [29,30],	 endomorophin	 1	 [31],	 taurine	
[22]	and	carnosine	[23]	have	been	demonstrated	to	prevent	Cd	
accumulation	 in	 the	 liver	 of	 animals,	 subjected	 to	 acute	 and	
subacute	 Cd‐intoxications,	 as	 in	 the	 case	 of	 carnosine	
administration	the	effect	reaches	87%	compared	to	the	normal	
control.	Considerable	improvement	of	the	liver	morphology	by	
these	antioxidants	has	been	observed.		
Vitamin	E	(applied	before	Cd‐intoxication)	has	been	shown	
to	 improve	 the	 level	 of	 GSH	 in	 male	 rats,	 subjected	 to	 acute	
intoxication	with	Cd(II)	 salt	 [32].	Panax	ginseng,	ascorbic	acid	
and	 garlic	 also	 improve	 the	 total	 antioxidant	 capacity	 of	 the	
liver	 in	 Cd‐treated	 animals	 [33,34].	 Detail	 histological	 studies	
about	 the	effect	of	 these	antioxidants	on	the	 liver	morphology	
of	 Cd‐intoxicated	 animals	 are	 needed	 to	 make	 a	 conclusion	
regarding	the	possible	application	of	these	compounds	for	 the	
treatment	of	Cd‐induced	hepatotoxicity.		
	
2.1.2.	Effect	of	antioxidants	on	Cd‐induced	hepatotoxicity	in	
subchronically	or	chronically	Cd‐intoxicated	animals	
	
Diphenyl	diselenide	[36,37],	melatonin	[38]	and	hesperetin	
[24]	have	been	proven	to	inhibit	the	level	of	LPO	in	the	liver	of	
Cd‐treated	mice.	The	effect	of	melatonin	[38]	however	on	iron	
homeostasis	 should	 be	 considered	 when	 this	 antioxidant	 is	
utilized	 for	 the	 treatment	 of	 Cd‐induced	 hepatotoxicity.	
Organoselenocyanates	 [39]	 have	 been	 also	 effective	 in	
restoring	 the	 activity	 of	 CAT	 in	 the	 liver	 of	 Cd‐intoxicated	
animals	but	the	compounds	do	not	recover	SOD	values.	Among	
the	 antioxidants	 screened	 on	 animals	 subchronically	 or	
chronically	 exposed	 to	Cd,	naringenin	 and	 the	 combination	of	
naringenin	(NGN),	vitamin	C	(Vit	C)	and	vitamin	E	(Vit	E)	seem	
to	be	the	most	effective	in	restoring	CAT	and	SOD	activity	of	the	
liver	(Table	2)	[40,41].	Histopathological	analysis	of	the	liver	of	
Cd‐intoxicated	 animals	 treated	with	 the	 combination	 of	 NGN,	
Vit	C	and	Vit	E	has	revealed	that	the	antioxidants	preserve	the	
normal	hepatic	architecture.		
	 	
2.2.	Effect	of	chelating	agents	on	Cd‐induced	hepatotoxicity	
in	mice,	subjected	to	acute	and	chronic	Cd‐intoxication	
	
A	comparative	study	on	the	effect	of	the	chelating	agents	N‐
(4‐methylbenzyl)‐4‐o‐(beta‐D‐galactopyranosyl)‐D‐glucamine‐		
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Table	3.	Chelating	agents,	tested	on	animal	models	for	the	treatment	of	Cd‐induced	hepatotoxicity.	
Chelating	agent	 Route	of	
administration	
Dose	 Animal	model	 Effect	 Ref.	
Mi‐ADMS		
MeBLDTC	
Information	not	
found	
Every	48	h	for	12	
days	
Male	mice,	injected	i.v.	
with	Cd(II)	chloride	
MeBLTDC	is	more	effective	on	equimolar	basis;	Mi‐ADMS	
however	could	be	applied	orally.	Both	compounds	improve	
trace	elements	homeostasis	in	Cd‐treated	mice.	
[44]	
DDC,	DMDC,	
CYCLAM,	TACPD,	
DMSA,	DMPS	
Information	not	
found	
Information	not	
found	
Mice	 DMDS,	CYCLAM,	TACPD	reduce	Cd	in	the	liver,	but	are	not	as	
effective	as	DMSA	and	DMPS.	The	effect	on	trace	elements	is	
not	studied.	
[45]	
Mi‐PDMA;	
Mi‐BDMA	
Mi‐ADMA	
i.p.	 4x1.5	mmol/kg	 Female	rats,	exposed	to	
chronic	Cd‐intoxication	
The	effectiveness	of	the	chelating	agents	increases	in	the	
order:	Mi‐ADMA	<	Mi‐BDMA	<	Mi‐PDMA	for	the	hepatic	Cd.	
The	most	effective	agent	was	the	most	toxic	as	well.	
[46]
Carbodithioate	
analogue	BLDTC	
and	CaDTPA		
i.p.	 Injected	every	48	
h	for	16	days	
Male	mice	intoxicated	with	
20	doses	of	Cd	(II)	chloride	
(single	dose	of	3	mg	kg‐1	
i.p.)	
The	antidotes	restore	partially	the	levels	of	Cu	and	Zn.	
BLDTC	is	more	effective	than	CaDTPA.	
[49]
Monensin	 p.o.		 14	mg/kg,	
applied	after	Cd‐
intoxication	
Male	mice,	subacute	
intoxicated	with	20	mg/kg	
Cd	(II)	acetate	for	14	days	
Monensin	recovers	AST,	ALT	and	ALP	values,	Cu	
homeostasis.	Zn	homeostasis	is	partially	recovered	by	the	
chelating	agent.	Monensin	reduces	Cd	concentration	in	liver	
by	50	%	compared	to	the	toxic	control	and	recovers	the	
hepatic	architecture.	
[47,48]	
Abbreviations:	 Mi‐ADMS:	 monoisoamyl	 meso‐2,3‐dimercaptosuccinate;	 MeBLDTC:	 N‐(4‐methylbenzyl)‐4‐O‐(beta‐D‐galactopyranosyl)‐D‐glucamine‐N‐
carbodithioate;	 DDC:	 diethyl	 dithiocarbamate;	 DMDC:	 dimethyl	 dithiocarbamate;	 CYCLAM:	 1,4,8,11‐tetraazacyclotetradecane;	 TACPD:	 1,4,8,12‐
tetraazacyclopentadecane;	 DMSA:	 2,3	 dimercaptosuccinic	 acid;	 DMPS:	 2,3‐dimercapto‐1‐propane	 sulfonate;	 Mi‐PDMA:	 meso‐2,3‐dimercaptosuccinic	 acid	
monoisopropylamide;	 Mi‐BDMA:	 meso‐2,3‐dimercaptosuccinic	 acid	 monoisobutylamide;	 Mi‐ADMA:	 meso‐2,3‐dimercaptosuccinic	 acid	 monoisoamylamide;	
BLDTC:	N‐benzyl‐4‐O‐(beta‐D‐galactopyranosyl)‐D‐glucamine‐N‐carbodithioate	CaDTPA:	calcium	trisodium	pentetate.	
	
	
N‐carbodithioate	 (MeBTDTC)	 and	 monoisoamyl	 meso‐2,3‐
dimercaptosuccinate	 (Mi‐ADMS)	 on	 Cd	 concentration	 in	
Cd‐treated	animals	has	demonstrated	 that	 the	chelating	agent	
MeBTDTC	 reduces	 more	 effectively	 the	 concentration	 of	 the	
toxic	 metal	 in	 the	 liver	 of	 animals,	 subjected	 to	 acute	 Cd‐
intoxication	but	 could	not	be	applied	orally	 in	 contrast	 to	Mi‐
ADMS	(Table	3)	 [44].The	effect	of	 the	chelating	agents	diethyl	
dithiocarbamate	 (DDC),	 dimethyl	 dithiocarbamate	 (DMDC),	
1,4,8,11‐tetraazacyclotetradecane	 (CYCLAM),	 1,4,8,12‐tetraaza	
cyclopentadecane	 (TACPD),	 2,3‐dimercaptosuccinic	 acid	
(DMSA),	 and	 2,3‐dimercapto‐1‐propane	 sulfonate	 (DMPS)	 on	
Cd	concentration	in	the	liver,	kidney	and	brain	of	mice,	exposed	
to	 Cd‐intoxication	 has	 been	 compared.	 The	 results	 by	
Srivastava	 et	 al.	 demonstrate	 that	 DMSA	 and	 DMPS	 are	most	
effective	 in	 reducing	 Cd	 [45],	 compared	 to	 DDC,	 DMDC,	
CYCLAM,	 TACPD.	 DMSA	 and	 DMPS	 however	 are	 hydrophilic	
compounds	 and	 their	 ability	 to	 bind	 the	 toxic	 metal	 ion,	
accumulated	in	the	intracellular	space	is	limited.	
The	 meso‐2,3‐dimercaptosuccinic	 acid	 mono‐N‐
alkylamides:	 Mi‐PDMA	 (meso‐2,3‐dimercaptosuccinic	 acid	
monoisopropylamide);	 Mi‐BDMA	 (meso‐2,3‐dimercapto‐
succinic	 acid	 monoisobutylamide)	 and	 Mi‐ADMA	 (meso‐2,3‐
dimercaptosuccinic	 acid	 monoisoamylamide)	 are	 effective	 in	
mobilizing	Cd	from	the	liver	but	are	not	that	much	effective	in	
reducing	the	Cd	concentration	in	the	kidneys.	At	optimum	dose	
Mi‐BDMA	reduces	renal	Cd	concentration	to	40%	compared	to	
the	toxic	control	[46].		
Our	 studies	 have	 demonstrated	 that	 the	 polyether	
ionophorous	 antibiotic	 monensin	 (applied	 p.o.	 as	 tetraethyl	
ammonium	salt)	to	mice,	subjected	to	subacute	Cd‐intoxication	
reduces	the	concentration	of	the	toxic	metal	ion	in	the	liver	up	
to	 50	 %.	 Furthermore	 this	 chelating	 agent	 abolished	 Cd‐
induced	alterations	 in	 iron	homeostasis	and	recovered	Cu	and	
Zn	 levels.	The	data	 from	 the	histopathological	 studies	showed	
that	monensin	attenuated	Cd‐induced	inflammation	in	the	liver	
confirming	 the	 positive	 effect	 of	 the	 antibiotic	 on	 the	 liver	 of	
mice,	exposed	to	subacute	Cd	intoxication	[47,48].	
	
3.	Antioxidants	and	chelating	agents,	screened	on	animal	
models	for	the	treatment	of	Cd‐induced	renal	dysfunction	
	
3.1.	Antioxidants	
	
	
3.1.1.	Antioxidants,	tested	on	animal	models	for	the	
treatment	of	renal	dysfunction,	induced	by	subacute	and	
acute	Cd‐intoxication	
	
The	kidneys	are	major	organs	that	аccumulate	metal	ions	in	
cases	 of	 metal	 intoxications.	 Cd	 has	 been	 shown	 to	 induce	
alterations	in	creatinine	(CR)	and	urea	in	the	urine	and	serum	
of	 Cd‐intoxicated	 animals	 [50].	 A	 decrease	 of	 the	 level	 of	 the	
antioxidant	enzymes	and	GSH	accompanied	with	an	increase	of	
the	 LPO	 in	 the	 kidneys	 of	 Cd‐intoxicated	 animals	 has	 been	
reported	 [51,52].	 On	 the	 morphological	 level	 Cd	 induces	
swelling	 of	 the	 epithelial	 cells	 of	 the	 renal	 tubules;	
degeneration	 and	 thickening	 of	 the	 basement	 membrane.	
Necrosis	 of	 the	 proximal	 renal	 tubules	 has	 been	 reported	 in	
animals,	 subjected	 to	 acute	 Cd‐intoxication	 [52].	 The	
antioxidants	 tested	 in	 the	 period	 1992‐2012	 years	 for	 the	
treatment	 of	 Cd‐induced	 renal	 dysfunction	 in	 animals,	
subjected	 to	 acute	 Cd‐intoxication,	 are	 presented	 in	 Table	 4.	
Diallyl	 tetrasulfide	 recovers	 the	 level	 of	 CR	 and	 urea	 in	 the	
serum	 and	 urine	 of	 Cd‐intoxicated	 rats.	 The	 antioxidant	 has	
been	 demonstrated	 to	 act	 as	 a	 chelating	 agent,	 reducing	 the	
concentration	of	 the	toxic	metal	 ion	by	70	%	compared	to	 the	
normal	control	[30].		
Garlic	 and	 onion	 extracts	 also	 effectively	 restore	 the	 total	
antioxidant	 capacity	 of	 the	 kidneys	 of	 Cd‐intoxicated	 animals	
[50].		
The	 honey	 bee,	 taurine,	 vitamin	 C	 and	 isoquercetin	 have	
been	shown	to	improve	the	antioxidant	defense	in	the	kidneys	
of	 animals,	 exposed	 to	 acute	 Cd‐intoxication	 [51‐53].	 Taurine	
and	 vitamin	 C	 have	 been	 demonstrated	 to	 recover	 CR	
concentration	 in	 the	 serum	 of	 mice,	 subjected	 to	 acute	 Cd‐
intoxication.	 Both	 antioxidants	 decrease	 MDA	 level,	 increase	
GSH	 and	 inhibit	 the	 accumulation	 of	 Cd	 in	 the	 kidneys.	 The	
histopathalogical	 analysis	 of	 kidneys	 of	 mice	 treated	 with	
taurine	 and	 Vitamin	 C	 prior	 to	 Cd‐intoxication	 demonstrates	
that	 the	 antioxidants	 preserve	 the	 normal	 renal	 architecture.	
Considering	that	Vitamin	C	is	an	oral	drug	it	might	be	the	best	
choice	 for	 the	 treatment	 of	 acute	 Cd‐intoxication	 [52].	 Caffeic	
acid	 also	 reduces	 Cd	 in	 the	 kidneys	 of	 animals,	 exposed	 to	
subacute	Cd‐intoxication	[54].		
Analysis	of	the	effect	of	caffeic	acid	on	Cd‐induced	elevation	
of	 Zn	 concentration	 in	 kidneys	 of	 Cd‐treated	 animals	
demonstrates	 that	 the	 antioxidant	 increases	 Zn	 concentration	
but	the	values	remain	lower	than	the	normal	controls.		
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Table	4.	Antioxidants,	tested	on	animal	models	for	the	treatment	of	renal	dysfunction	induced	by	acute	and	subacute	Cd‐intoxications.	
Antioxidant	 Route	of	
administration	
Dose	 Animal	model	 Effect	 Ref.	
Diallyl	
tetrasulfide	
(DTS)	
p.o.		 40	mg/kg	b.w./day	for	3	
weeks,	co‐administrated	with	
Cd(II)	
Rats,	s.c.	intoxicated	
with	Cd(II)	chloride	
(3	mg/kg/d	for	3	
weeks)	
DTS	recovers	CR	and	urea	in	the	serum	and	in	urine.	DTS	
decreases	Cd	by	70	%.	DTS	also	inhibits	Cd‐induced	LPO	
and	increases	GSH	and	antioxidant	enzymes.	
[30]
Garlic	and	
onion	extract	
p.o.		 0,	5	mL/100	g	b.w.	and	1	
mL/100	g	b.w.	extract	prior	to	
Cd‐	intoxication.	The	treatment	
continued	with	Cd(II)	
administration.		
Rats	‐	intoxicated	p.o.	
with	1,5	mg	Cd/100	g	
b.w.	for	3	weeks	
Both	extracts	restore	the	antioxidant	defense	in	the	
kidneys	but	onion	is	more	effective.	
[50]	
Honey	bee	
(HB)	
p.o.	 100;	250	mg/kg	b.w.,	co‐
administrated	with	Cd(II)	
Mice,	acutely	
intoxicated	with	
Cd(II)	chloride	‐	2	
mg/kg	b.w.		
Recovery	of	the	GSH	level	has	been	observed	in	the	
animals	treated	with	HB	accompanied	with	decrease	of	
the	LPO.	
[51]
Taurine,		
Vitamin	C	
Taurine	‐i.p.	
Vitamin	C	‐	orally	
100	mg/kg	b.w.	once	daily	for	
5	days,	applied	prior	to	
treatment	with	Cd(II)	
Mice,	acutely	
intoxicated	with	4	
mg/kg	Cd(II)	chloride	
(i.p.	for	3	days)	
Both	antioxidants	cause	50%	reduction	of	urea	in	the	
serum	and	recover	CR	in	the	Cd‐treated	animals.	The	
antioxidants	decrease	MDA,	but	the	values	remain	10%	
higher	than	the	control.	A	70%	decrease	of	Cd	in	the	
kidneys	has	been	observed	as	a	result	of	the	
administration	of	the	antioxidants.	The	histological	
analysis	has	been	demonstrated	normal	appearance	of	
the	glomeruli	and	tubules	in	the	kidneys	of	Cd‐treated	
animals,	receiving	antioxidants.	
[52]	
Isoquercetin	 Information	not	
found	
Information	not	found	 Mice,	acutely	
intoxicated	i.p	with	
Cd(II)	chloride	‐	2	
mg/kg	b.w.	
The	antioxidant	has	been	shown	to	attenuate	Cd‐induced	
alterations	in	kidneys	and	liver.	
[53]	
Caffeic	acid	 i.p.,		 10	μmol/kg	per	day	for	7	days	
coadministrated	with	Cd(II)	
Mice,	exposed	i.p.	to	
Cd(II)	chloride	(1	
mg/kg/day	for	7	
days)	
Caffeic	acid	completely	recovers	antioxidant	defense	
system	in	the	kidneys;	reduces	Cd	level	(22	%);	recovers	
partially	Zn	concentration.	Zn	concentration	remains	20	
%	lower	than	the	control.	
[54]	
	
	
Table	5.	Antioxidants,	applied	for	the	treatment	of	Cd‐induced	oxidative	stress	in	the	kidneys	of	animals,	subjected	to	subchronic	and	chronic	Cd‐intoxications.	
Antioxidant	 Route	of	
administration	
Dose	 Animal	model	 Effect	 Ref.	
Glycyrrhizin,	
cysteine,	
glycine	
Information	not	
found	
Information	not	found	 Rats,	subjected	to	
chronic	intoxication	
with	5	μM	Cd(II)	
chloride/kg	b.w.	/day	
5	times	a	week	for	22	
weeks	
The	antioxidants	reduce	chronic	Cd‐toxicity.	 [62]
Melatonin	 p.o		 4	μg/mL	(optimum	dose)	for	8	
weeks	applied	together	with	
Cd(II)	
Female	and	male,	
subchronically	
intoxicated	with	50	
μg	Cd/mL	as	Cd(II)	
chloride	for	8	weeks	
Melatonin	decreases	Cd	level	by	23	%	compared	to	toxic	
control;	the	antioxidant	however	decreases	hepatic	iron	
to	14	%	compared	to	the	toxic	control.	The	Cd‐induced	
alteration	in	Fe	homeostasis	was	not	recovered	by	the	
antioxidant.	
[38]	
Quercetin	
(QE)	
i.p.	 50	mg/kg/day	for	9	weeks	
along	with	Cd(II)	
Rats,	intoxicated	s.c.	
1.2	mg/kg/day	Cd(II)	
for	9	weeks	
QE	prevents	Cd‐induced	overexpression	of	iNOS	and	
COX‐2.	
[58]
N‐
acetylcysteine	
(NAC)	
p.o.		 0,5	%	when	applied	together	
with	Cd;	2	%	when	used	after	
intoxication.	The	antioxidant	
has	been	applied	in	co‐
administration	with	cadmium	
and	after	the	intoxication	
Rats,	intoxicated	with	
CdCl2	for	3	months	
NAC	recovers	SOD	and	CAT.	GSH	is	no	affected	by	the	
antioxidant.	In	both	cases	NAC	preserves	the	normal	
appearance	of	the	renal	proximal	tubules	
[55]	
NAC	 p.o.	 120	mg/kg/day	 Female	rats,	
chronically	exposed	
to	20	mg/L	Cd(II)	
NAC	decreases	LPO,	but	the	concentration	of	Cd	in	the	
kidney	is	not	affected.	GSH,	SOD	and	CAT	have	not	been	
recovered	by	the	antioxidant.	
[56]
Naringenin	
(NGN)	
p.o.	 50	mg/kg/day	for	4	weeks,	
together	with	Cd(II)	
administration	
Rats,	exposed	to	
subchronic	
intoxication	with	
Cd(II)	chloride	5	
mg/kg	for	4	weeks	
NGN	preserves	Cd‐induced	alterations	in	the	antioxidant	
enzymes;	GSH	and	LPO.	NGN	ameliorates	Cd‐induced	
alterations	in	the	renal	architecture.	
[57]
QE	 p.o.		 50	mg/kg/	day	for	4	weeks,	co‐
administrated	with	Cd(II)	
Rats,	exposed	to	
subchronic	
intoxication	with	
Cd(II)	chloride	5	
mg/kg	for	4	weeks,	
co‐administrated	
with	Cd(II)	
QE	recovers	CR	and	urea	and	attenuates	Cd‐induced	
alterations	in	the	antioxidant	status	in	the	kidneys;	QE	
ameliorates	Cd‐induced	pathology	of	the	kidneys.	
[59]	
QE;	Vitamin	C	
and	Vitamin	E	
p.o.	 Information	not	found	 Rats	 The	combination	of	QE	plus	vitamin	C	and	vitamin	E	
improves	the	renal	morphology	and	attenuates	Cd‐
induced	alterations	in	antioxidant	defence	system.	
[60]
Telmisartan	 p.o.	 1	mg/kg/daily	started	one	
week	before	Cd	administration	
and	continued	for	10	weeks	
Mice,	treated	with	1.2	
mg	Cd/kg	day	for	9	
weeks	
The	antioxidant	improves	Zn	homeostasis,	decreases	the	
concentration	of	Cd	and	inhibits	the	LPO.	Telmisaran	also	
decreases	TNF‐a	and	NO	elevated	by	Cd.	
[63]	
Herbal	
adaptogens	
p.o.	after	Cd‐
intoxication	
0,	1	%	powder	in	the	feed,	
applied	for	2	weeks	
Chicks,	exposed	to	
chronic	cadmium	
intoxication	100	
ppm/	day	for	28	days	
Asperagus	recemosus, Angrographis	paniculata	are	most	
effective	among	eight	adaptogens	tested.	These	
adaptogens	recover	GSH;	reduce	LPO	to	normal	values	
and	decrease	Cd	in	the	kidneys	by	50	%.	The	serum	CR	
however	remains	higher	than	the	normal	control.	
[61]
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Table	6.	Chelating	agents,	screened	on	animal	models	for	mobilization	of	Cd	in	kidneys.	
Chelating	agent	 Administration	
route	
Dose	 Animal	model	 Effect	 Ref.	
MPhEDMS	
MPhPDMS	
MPhOEDMS	
i.p.	 0,5	mmol/kg/day	
for	4	days	
Rats	 The	chelating	agents	significantly	deplete	hepatic	and	
renal	Cd	compared	with	the	toxic	control	
[64]	
MBzDMS	 i.p.;	i.v.;	p.o.	 Rats/mice	 MBzDMS	was	found	to	be	less	effective	than	Mi‐ADMS	in	
mobilizing	Cd.	
[68]	
TRIEN,	TREN,	
TETREN,	PENTEN	
Rats,	intoxicated	with	
Cd	4	days	before	
chelation	
The	chelating	agents	cause	significant	renal	damage.	 [65]
Mi‐PDMA;	
Mi‐BDMA	
Mi‐ADMA	
i.p.	 4x1.5	mmol/kg Famale	rats,	exposed	
to	chronic	Cd‐
intoxication	
The	chelating	agents	do	not	possess	optimized	structure	
between	LD50	and	effectiveness.	
[46]
DDC,	DMDC,	CYCLAM,	
TACPD,	DMSA,	DMPS	
Information	not	
found	
Information	not	
found	
Mice	 DMDS,	CYCLAM,	TACPD	reduce	Cd	in	the	kidneys.	The	
therapeutic	index	of	the	chelating	agents	decreases	in	the	
order:	DMSA>DMPS>DMDC	
[45]	
MFA;	MSFA;	MAFA	 Information	not	
found	
Information	not	
found	
Rats	 The	chelating	agents	affect	the	trace	elements	
homeostasis.	
[66]	
Diethylcarbamate	 p.o.	 100	mg/kg	b.w. Rats,	subjected	to	
acute	intoxication	
with	Cd	for	60	days	
(40	mg/kg/day)	
The	chelating	agent	reduces Cd	in	kidney	by	60	%.	 [69]
DFO	 p.o.	 Information	not	
found	
Rats,	subjected	to	
acute	intoxication	
with	Cd	for	60	days	
(20	and	40	
mg/kg/day)	
DFO	improves	Fe	homeostasis	and	reduces	Cd	in	the	
body.	
[67]
Monensin	 p.o.	 14	mg/kg	 Mice,	subjected	to	
subactute	Cd	
intoxication	for	2	
weeks		
Monensin	improves	iron	homeostasis	and	reduces	Cd	
from	50	%	(liver)	to	90	%	(heart).	
[47]	
Abbreviations:	Monoaralkyl	 esters	 of	 meso‐2,3‐dimercaptusuccinic	 acid:	 HOOCCH(SH)CH(SH)COOR,	 where	 R	 =	 phenylethyl	 (CH2)2C6H5,	 MPhEDMS;	 R	 =	 3‐
phenylpropyl	 ((CH2)3C6H5),	 MPhPDMS;	 and	 R	 =	 2‐phenoxyethyl	 (CH2)2OC6H5,	 MPhOEDMS;	 Triethylenetetramine	 dihydrochloride	 (TRIEN),	 Tris(2‐
aminoethyl)amine	trihydrochloride	(TREN),	Tetraethylenepentamine	pentahydrochloride	(TETRAEN),	Pentaethylenehexamine	hexahydrochloride	(PENTAEN);	
Alpha‐mercapto‐beta‐(2‐furyl)	 acrylic	 acid	 (MFA),	 alpha‐mercapto‐beta‐(5‐sodiumsulfonate,	 2‐furyl)	 acrylic	 acid	 (MSFA)	 and	 alpha‐mercapto‐beta‐(5‐
acetoxymethyl,	2‐furyl)	acrylic	acid	(MAFA);	Desferrioxamine	(DFO).	
	
	
It	should	be	pointed	out	that	in	contrast	to	the	antioxidants	
discussed	above	the	caffeic	acid	has	been	applied	i.p.,	therefore	
it	 might	 not	 be	 the	 best	 choice	 for	 the	 treatment	 of	 Cd‐
intoxication	[54].	
	
3.1.2.	Antioxidants,	tested	on	animal	models	for	the	
treatment	of	renal	dysfunction,	induced	by	subchronic	and	
chronic	Cd‐intoxications	
	
The	 antioxidants	 screened	 on	 animals,	 exposed	 to	
subchronic	 and	 chronic	 Cd‐intoxications,	 are	 summarized	 in	
Table	5.	
N‐acetylcysteine	 (NAC)	 salt	 is	 effective	 in	 improving	 renal	
function	 of	 male	 and	 female	 rats,	 exposed	 to	 chronic	 Cd‐
intoxication.	In	both	cases	however	NAC	does	not	recover	GSH	
[55,56].	
Naringenin	 (NGN),	Quercetin	 (QE),	QE+Vitamin	C+Vitamin	
E	 have	 been	 demonstrated	 to	 recover	 CR	 and	 urea	 levels	 in	
serum	 and	 urine	 in	 animals,	 subjected	 to	 subchronic	 Cd‐
intoxication	[57‐60].	Furthermore,	these	antioxidants	decrease	
LPO	in	the	kidneys	and	improve	GSH	and	antioxidant	enzymes	
levels.	 The	 histopatological	 analysis	 of	 the	 renal	 tissue	 of	 Cd‐
treated	 animals,	 receiving	 NGN	 or	 QE	 reveals	 that	 these	
antioxidants	preserve	the	normal	renal	architecture	[57‐60].		
The	 herbal	 adaptogens:	 Withania	 somnifera,	 Ocimum	
sanctum,	 Asperagus	 recemosus,	 Andrographis	 paniculata,	
Asphaltum	 panjabinum	 (Shilajith),	 Gymnema	 sylvestre,	
Spirulina	 platensis,	 and	 Panex	 ginseng	 have	 been	 tested	 to	
prevent	Cd	bioaccumulation	 in	 chicks,	 exposed	 to	 chronic	Cd‐
intoxication	[61].	The	herbal	adaptogens	Asperagus	recemosus	
and	 Andrographis	 paniculata,	 applied	 p.o.,	 reduce	 Cd	
concentration	 in	 kidney	 by	 50%	 compared	 to	 the	 control;	
inhibit	 LPO,	 and	 recover	GSH	 level.	 CR	values	 in	 the	 serum	of	
Cd‐treated	 animals,	 receiving	 antioxidants,	 however	 remain	
higher	than	the	normal	control	(25%)	[61].	
3.2.	Chelating	agents	
	
The	monoaralkyl	esters	(HOOCCH(SH)CH(SH)COOR,	where	
R	 =	 phenylethyl	 ((CH2)2C6H5),	MPhEDMS;	 R	 =	 3‐phenylpropyl	
((CH2)3C6H5),	 MPhPDMS;	 and	 R	 =	 2‐phenoxyethyl	
((CH2)2OC6H5).	 MPhOEDMS)	 of	 meso‐2,3‐dimercaptusuccinic	
acid	 have	 been	 effective	 in	 reducing	 the	hepatic	 and	 renal	 Cd	
concentration	 in	 Cd‐intoxicated	 rats,	 but	 no	 information	
regarding	 the	 effect	 of	 the	 chelating	 agents	 on	 the	 trace	
elements	 homeostasis	 has	 been	 presented.	 Furthermore,	 the	
esters	of	DMSA	have	been	administrated	i.p.,	which	could	be	a	
disadvantage	 of	 these	 agents	 over	 others	 chelators	 for	 the	
treatment	of	Cd‐intoxication	(Table	6)	[64].	
Among	 the	 chelating	 agents,	 the	 polyamines:	
triethylenetetraamine	 dihydrochloride	 (TRIEN),	 tris(2‐amino	
ethyl)amine	trihydrochloride	(TREN),	tetraethylene	pentamine	
pentahydrochloride	 (TETRAEN),	 and	 pentaethylene	 hexamine	
hexahydrochloride	(PENTAEN)	increase	Cd	in	 the	urine	of	Cd‐
exposed	 rats	 (Table	 5)	 [65].	Oliguria	 and	 anuria	 induced	 as	 a	
result	 of	 the	 application	 of	 these	 chelating	 agents	 have	 been	
observed	 in	 Cd‐treated	 animals,	 suggesting	 a	 significant	 renal	
damage	[65].	
DMSA	and	DMPS	reduce	Cd	in	the	kidneys	of	mice,	exposed	
to	Cd	 intoxication,	but	DMSA	is	not	effective	 in	eliminating	Cd	
from	 intracellular	 deposits.	 Therefore	 this	 agent	 is	 not	 very	
suitable	for	the	treatment	of	chronic	Cd‐intoxication	[46].	
The	chelating	agents	alpha‐mercapto‐beta‐(2‐furyl)	acrylic	
acid	 (MFA),	 alpha‐mercapto‐beta‐(5‐sodiumsulfonate,	 2‐furyl)	
acrylic	 acid	 (MSFA)	 and	 alpha‐mercapto‐beta‐(5‐acetoxy	
methyl,	 2‐furyl)	 acrylic	 acid	 (MAFA)	 have	 been	 found	 to	 be	
effective	in	mobilizing	Cd	in	Cd‐treated	animals,	but	their	affect	
on	trace	element	homeostasis,	especially	Cu	and	Zn,	should	be	
considered	in	chelation	therapy	with	these	agents	[66].	
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Table	7.	Antioxidants,	tested	on	animal	models	for	the	treatment	of	Cd‐induced	toxicity	in	the	testes	(acute	Cd‐intoxication).	
Antioxidant	 Route	of	
administration	
Dose	 Animal	model	 Effect	 Ref.	
Ascorbic	
acid	
p.o.	 200	mg/100	g	b.w.	 Rats,	exposed	to	acute	
intoxication	with	0.2	and	
0.3	mg/100	g	b.w.	Cd(II)	
(s.c.)	
The	antioxidant	prevents	germ	cell	apoptosis;	
restores	testosterone;	3‐beta	and	17‐beta	HSD.	
[71,72]
Vitamin	C	
Vitamin	E	
i.p.	 Vitamin	C	10	mg/kg	b.w.;	
Vitamin	E	‐	100	mg/kg	b.w.,	
concurrent	with	Cd(II)	
Mice,	intoxicated	with	
Cd(II)	chloride	1	mg/kg	
b.w.	i.p.	
Both	vitamins	improve	sperm	count,	decrease	sperm	
abnormality	percentage	and	partially	improve	total	
antioxidant	capacity	in	the	testes.	
[73]	
Hemin	 p.o.	 40	μmol/kg	b.w.,	applied	one	
day	before	Cd‐intoxication	and	
continued	for	2	days	after	Cd‐
administration	
Rats,	exposed	to	acute	
intoxication	with	2	mg/kg	
Cd(II)	chloride,	i.p.	
Hemin	restores	the	active	spermatogenesis	but	the	
values	of	testosterone	remain	lower	than	the	normal	
control.	The	antioxidant	preserves	the	normal	
histoarchitectute	of	the	testes	of	Cd‐treated	rats.	
[74]	
(PhSe)2	 p.o.	 400	μmol/kg	b.w.,	applied	30	
min	after	Cd‐administration	
Mice,	exposed	to	Cd(II)	
chloride	
(5	mg/kg	b.w.,	i.p.)	
The	antioxidant	partially	decreases	Cd‐induced	LPO	
and	increases	ascorbic	acid	in	the	testes.	Moderate	
edema	is	observed	in	the	testicular	tissues	of	Cd‐
treated	animals,	receiving	(PhSe)2.	
[75]
Vitamin	E	
and	Q10	
Information	not	
found	
Information	not	found	 Rats,	exposed	to	0,4	
mg/kg		
Both	antioxidants	recover	GSH,	SOD	and	GR	and	
GSH‐Px	to	normal	values.	
[76]	
Melatonin	 i.p.	 5	mg/kg	b.w.	every	8th	hour,	
beginning	8	hours	before	Cd‐
administration	
Mice,	exposed	to	Cd(II)	
chloride	(2	mg/kg),	i.p.	
The	antioxidant	inhibits	Cd‐induced	testicular	germ	
cell	apoptosis.	
[77]
	
	
	
DFO	and	monensin	are	most	effective	in	the	elimination	of	
Cd	in	animals,	exposed	to	acute	and	subactute	Cd‐intoxication.	
Both	 agents	 have	 been	 demonstrated	 to	 improve	 iron	
homeostasis	and	could	be	applied	orally	[46,67].		
	
4.	Antioxidant	and	chelating	agents,	tested	on	animal	
models	for	the	treatment	of	Cd‐induced	testicular	
dysfunction	
	
Cd	 induces	 reduction	of	 sperm	motility,	 testosterone,	 3‐β‐
hydroxysteroiddehydrogenase	(3‐β‐HSD),	17‐β‐hydroxysteroid	
dehydrogenase	 (17‐β‐HSD)	 and	 an	 increase	 of	 the	percentage	
of	 abnormal	 sperm	 in	 animals,	 subjected	 to	 Cd	 intoxication.	
Histopathological	 analysis	 of	 testicular	 tissue	 of	 animals,	
administrated	 Cd,	 reveals	 that	 the	 toxic	 metal	 causes	 severe	
lesions	 in	 the	 form	 of	 diffuse	 necrosis	 affecting	 the	 germinal	
layer	 in	 the	 seminiferous	 tubules	 and	 interstitial	 tissue	 [70].	
Higher	 levels	 of	 lipid	 peroxidation	 in	 testes	 compared	 to	 the	
normal	control	have	been	reported	in	animals,	receiving	Cd.	Cd	
decreases	 the	 activity	 of	 antioxidant	 enzymes:	 SOD,	 CAT	 and	
GSH	level	in	the	testes	[70].	
	
4.1.	Antioxidants	
	
4.1.1.	Antioxidants,	screened	on	animal	models	for	the	
treatment	of	oxidative	stress	in	testes	of	animals,	exposed	to	
acute	Cd‐intoxication	
	
The	 antioxidants,	 screened	 on	 animal	 models	 for	 the	
treatment	 of	 oxidative	 stress	 in	 testes	 of	 animals,	 exposed	 to	
acute	 Cd‐intoxication,	 are	 summarized	 in	 Table	 7.	 Vitamins	 C	
and	 E	 alone	 or	 in	 combination,	 applied	 concurrent	 with	 Cd‐
intoxication	 have	 been	 shown	 to	 restore	 testosterone	 and	
testicular	 key	 androgenic	 enzymes	 3‐β‐hydroxysteroid	
dehydrogenase	 and	 17‐β‐hydroxysteroid	 dehydrogenase	
[71,72].	Depending	 on	 the	 dose	 of	 Cd,	 Vitamins	 C	 and	E	 have	
been	demonstrated	to	recover	partially	or	completely	the	total	
antioxidant	 capacity	 in	 the	 testes.	 Both	 vitamins	 decrease	
sperm	abnormality	percentage	and	 improve	sperm	count	 [71‐
73,76].	
	
4.1.2.	Antioxidants,	screened	on	animals	for	the	treatment	of	
oxidative	stress	in	testes	of	animals,	exposed	to	subchronic	
and	chronic	Cd‐intoxication	
	
The	 antioxidants	 tested	 on	 Cd‐induced	 oxidative	 stress	 in	
animals,	exposed	to	subchronic	and	chronic	Cd	intoxication,	are	
presented	in	Table	8.	
Vitamin	 E	 and	 β‐carotene	 improve	 some	 hematological	
paramets	 (Hb,	 TEC,	 TLC)	 in	 rats,	 subjected	 to	 subchronic	 Cd‐	
intoxication	and	significantly	recover	sperm	quality	[80,81].	α‐
tocopherol	 reduces	 the	degree	of	necrosis	of	 the	 seminiferous	
tubules	induced	by	2	mg/kg	b.w.	Cd(II)	chroride,	injected	i.p.	in	
rats	 for	 5	 weeks	 [78,79].	 The	 antioxidant	 however	 has	 been	
demonstrated	not	 to	 have	protective	 effect	 in	 higher	 doses	 of	
Cd(II)	chloride	[80]	and	applied	before	Cd‐intoxication.		
α‐Lipoic	 acid,	 applied	 along	 with	 Cd,	 also	 recovers	
testicular	 key	 androgenic	 enzymes	 and	 preserves	 the	 normal	
testicular	architecture	[81].		
Among	the	antioxidants,	screened	on	animal	models	for	the	
treatment	 of	 Cd‐induced	 toxicity	 in	 the	 testes	 of	 animals	
exposed	 to	 subchronic	 or	 chronic	 Cd‐intoxication,	 hesperetin	
(HP),	 diallyl	 tetrasulfide	 (DTS)	 and	 α‐tocopherol	 possess	
chelating	 effect,	 reducing	 the	 concentration	 of	 toxic	metal	 ion	
[70,82‐84].	 The	 protection	 by	 these	 antioxidants	 is	 further	
substantiated	by	reduction	of	Cd‐induced	pathological	changes	
in	the	testicular	tissue.		
	
4.2.	Chelating	agents	
	
The	 chelating	 agents	 screened	 on	 animal	 models	 for	 the	
treatment	 of	 Cd‐induced	 toxicity	 in	 testes	 are	 summarized	 in	
Table	 9.	 Diethyldithiocarbamate	 (DED)	 alone	 decreases	 Cd	
concentration	in	testes,	but	redistribution	of	the	toxic	metal	ion	
to	 the	 kidneys	 and	 brain	 has	 been	 observed	 [91,92].	 The	
combinations	 of	 DED	 and	 N‐benzyl‐D‐glucamine	 dithio	
carbamate	 (BGD)	 or	 DED	 and	 N‐p‐isopropylbenzyl‐D‐
glucaminedithiocarbamate	 (PBGD)	 diminish	 Cd	 level	 in	 testes	
without	 causing	 its	 redistribution	 in	 other	 tissues	 [91,92].	
However,	 these	 combinations	 of	 the	 chelating	 agents	 increase	
Cd	 concentration	 in	 the	 blood	 and	 Cd	 distribution	 in	 the	 red	
blood	cells	[91,92].	Disulfiram	(DSF)	has	been	demonstrated	to	
be	more	 effective	 compated	 to	DED	 in	 reducing	 the	 testicular	
damage,	caused	by	Cd	[93].		
Meso‐2,3‐dimercaptosuccinic	acid	(DSMA)	applied	alone	or	
in	combination	with	(PhSe)2	inhibits	the	toxicity	caused	by	2.5	
mg/kg	b.w.	Cd(II)	 chloride	 in	mice.	Both	compounds	however	
are	 ineffective	 in	 restoring	 the	 SOD	 activity	 and	 the	 level	 of	
ascorbic	 acid,	 induced	 by	 5	 mg/kg	 Cd(II)	 chloride	 [94].	
Diphenyl	diselenide	applied	s.c.	30	min	after	Cd	administration	
in	 mice	 elevates	 Cd‐induced	 injury	 in	 the	 testes,	 but	 when	
administrated	at	higher	dose	 (100	μmol/kg),	 applied	alone	or	
together	 with	 2,3‐dimercapto‐1‐propanesulfonic	 acid	 (DMPS)	
decreases	 Cd‐induced	 toxicity	 and	 improves	 the	 level	 of	 δ‐
aminolevulinic	acid	dehydratase	(δ‐ALA‐D)	[95,96].	
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Table	8.	Antioxidants,	screened	on	animal	models	for	the	treatment	of	Cd‐induced	oxidative	stress	in	testes	of	animals,	exposed	to	subchonic	and	chronic	Cd‐
intoxication.	
Antioxidant	 Route	of	
administration	
Dose	 Animal	model Effect Ref.
β‐carotene	 i.g.	 250	IU/kg,	concurrent	with	
Cd(II)	
Rats,	intoxicated	with	
Cd(II)	chloride	
(2	mg/kg	b.w.	‐	
intragastrically	for	3	and	6	
weeks)	
The	antioxidant	restores	the	activity	of	SOD	and	GSH	
in	the	testes	and	brain.	
[78]	
Vitamin	E‐,	
β‐carotene	
p.o.	by	gavage	 100	mg/kg	Vitamin	E;	10	
mg/kg	β‐carotene	for	15	days,	
concurrent	with	Cd(II)	
Rats,	exposed	to	Cd(II)	
chloride	
(5mg/kg	b.w.	for	15	days	
Both	vitamins	alone	or	in	combination	improve	
sperm	concentration,	motility	(%)	and	recover	the	
weight	of	the	testes	and	epididymis,	and	decrease	
the	abnormal	sperm.	
[79]
α‐tocopherol	 i.p.	 0,1	mL	applied	five	days	before	
Cd‐intoxication	
Rats,	exposed	to	Cd	i.p.	
Doses	of	Cd(II)	chloride	‐	
1,	2	,	4,	9	mg/kg	b.w.	for	5	
weeks	
The	antioxidant	does	not	show	protective	effect	on	
higher	doses	of	Cd(II)	chloride	‐	4	and	8	mg/kg.		
[80]
Organoseleniu
m	compound	
(Ebselen)	
Information	not	
found	
Information	not	found	 Mice,	administrated	i.p.	
Cd(II)	chloride	
Ebselen	recovers	the	levels	of	ascorbic	acid;	the	
activity	of	delta‐ALA‐D	and	inhibits	LPO	in	the	
testes.	
[85]	
Diallyl	
sulphide	
(DAS)	
Information	not	
found	
Information	not	found	 Rats,	exposed	to	2,	5	
mg/kg	Cd(II)	chloride	five	
times	a	week	for	4	weeks	
DAS	restores	total	antioxidant	capacity	in	the	testes	
and	restores	testosterone	levels;	3‐beta‐HSD	and	17‐
beta‐HSD.	
[86]
Onion	and	
garlic	
p.o.	 0,	5	mL/100	g	bw.	
1	mL/100	g	b.w.;	applied	1	
week	before	intoxication	and	
continued	with	Cd‐	
administration	
Rats,	intoxicated	with	1,5	
mg	Cd/100	g	b.w.	daily	
p.o.	for	3	weeks	
The	onion	and	combination	of	onion	and	garlic	are	
more	effective	than	garlic	alone.	The	antioxidants	
improve	sperm	motility,	decrease	abnormal	sperm	
rate.	They	partially	recovered	GSH,	SOD	and	reduce	
LPO.	
[87]
α‐lipoic	acid	 p.o.	 35	mg/kg,	concurrent	with	
Cd(II)	
Rats,	exposed	to	2	mg/kg	
Cd(II)	chloride,	i.p.	for	28	
days	
The	antioxidant	ameliorates	testicular	key	
androgenic	enzymes	and	preserves	the	normal	
histoarchitecture	of	the	testes.	
[81]	
Guarana	
(Paullinia	
cupana)	
p.o.	or	i.p.	 Pretreatment	for	56	days	with	
2	mg/kg	b.w.,	1.15	mg/kg	i.p.	
single	dose	
Rats P.	Cupana	reduces	inflammatory	cell	response	and	
improves	the	morphology	of	Leidyg	cells.	
[88]
Tribulus	
terrestris	Linn	
(TT);	α‐
tocopherol	
p.o.	 TT	‐	5	mg/kg	b.w.	daily;	 ‐
tocopherol	‐	75	mg/kg	b.w.	
daily	for	6	weeks	
Rats,	exposed	to	Cd(II)	
chloride	treatment	(3	
mg/kg	b.w.)	once	a	week	
for	6	weeks	
TT	reduces	Cd by	50	%,	α‐tocopherol	‐	80	%.	Both	
antioxidants	improve	total	antioxidant	capacity	of	
the	testes	and	preserve	the	normal	histoarchitecture	
of	the	testes.	The	α‐tocopherol	is	more	effective	than	
TT	at	the	doses	applied.
[82,83]
Quercetin	
(QE)	
p.o.	 75	mg/kg	daily	for	2	weeks,	
concurrent	with	Cd(II)	
Mice,	treated	with	Cd(II)	
chloride	(4	mg/kg	b.w.)	
p.o.	for	2	weeks	
The	antioxidant	inhibits	germ	cell	apoptosis	and	LPO	
induced	by	Cd.	QE	recovers	SOD	and	improves	GSH	
level.	
[89]	
Ginger	 p.o.	 Information	not	found	 Rats The	antioxidant	reverses	the	Cd‐induced	toxicity	in	
the	testes.	
[90]
Hesperetin	
(HP)	
p.o.	 40	mg/kg	b.w.	along	with	
Cd(II)	
Rats,	intoxicated	with	3	
mg/kg	b.w.	Cd	(II)	
chloride	s.c.	for	21	days	
HP	reduces	Cd	concentration	in	the	testes	by	50	%;	
abolishes	Cd‐induced	pathology	in	testicular	tissue	
and	improves	the	antioxidant	total	capacity.	
[70]
Diallyl	
tetrasulfide	
(DTS)	
p.o.	 40	mg/kg	b.w.	concurrent	with	
Cd(II)	
Male	rats,	intoxicated	with	
3	mg/kg	Cd	s.c.	for	3	
weeks	
DTS	reduces	Cd	accumulation	in	the	testes,	improves	
the	activity	of	antioxidant	enzymes	and	GSH	level	in	
the	testes,	and	preserves	the	normal	
histoarchitecture	of	the	testes.	
[84]	
	
	
Table	9.	Chelating	agents,	applied	for	treatment	of	Cd	concentration	in	testes	of	animals,	subjected	to	Cd‐intoxication.	
Chelating	
agent	
Route	of	
administration	
Dose	 Animal	model Effect Ref.
DED;	BGD;	
PBGD	
i.p.	 0.4,	1	or	3	mmol/kg	
b.w.,	after	Cd‐treatment	
Rats,	intoxicated	with	3	
mg/kg	Cd(II)	s.c.	
Combinations	of	DED	and	BGD	or	DED	and	PBGD	
prevented	sterility	caused	by	Cd	and	decrease	Cd	
in	the	testes.		
[91,92]
Mi‐ADMS	 i.p.	 0,5	mmol/kg	b.w.,	after	Cd‐
intoxication	
Rats,	intoxicated	with	0,03	
mmol/kg	Cd(II)	chloride,	
i.p.	
The	chelating	agent,	applied	1	h	after	Cd‐
administration	reduces	Cd‐induced	apoptosis	and	
DNA	fragmentation.	
[98,99]
DSF;	DED	 i.p.	 DED	‐	0,	1;	1	mmol/kg	b.w.;	
DSF	‐	0,05;	5	mmol/kg	b.w.	
applied	after	Cd‐intoxication
Rats,	injected	(s.c.)	with	3	
mg/kg	Cd	
DSF	inhibits	Cd‐induced	LPO;	reduces	testicular	
damage	caused	by	Cd	and	restores	Fe	
homeostasis.
[93]
(PhSe)2;	DMSA	 Information	not	
found	
Information	not	found	 Mice,	exposed	to	2.5	
mg/kg	b.w.	Cd(II)	chloride	
or	5	mg/kg	b.w.	Cd(II)	
chloride	(i.p)	
Both	compounds	in	combination	or	alone	do	not	
improve	the	ascorbic	acid	and	SOD	activity	in	
mice,	exposed	to	5	mg/kg	Cd(II)	chloride.	
[94]	
(PhSe)2;	DMPS	 Information	not	
found	
Information	not	found	 Mice,	exposed	to	2.5	
mg/kg	b.w.	Cd(II)	chloride	
or	5	mg/kg	b.w.	Cd(II)	
chloride	(i.p)	
The	chelating	agents	partially	inhibit	Cd‐induced	
toxicity	caused	by	2.5	mg/kg	Cd(II)	chloride.	
Combined	therapy	decreases	Cd	concentration	in	
testes	and	recovers	plasma	AST,	elevated	by	5	
mg/kg	Cd(II)	chloride.
[95]
(PhSe)2	 s.c.	 5	micromol/kg	b.w.,	in	30	min	
after	Cd	five	weekly,	4	weeks	
Mice,	exposed	to	
subchronic	intoxication	
with	Cd(II)	chloride	
(s.c.	2.5	mg/kg,	five	times	
weekly,	4	weeks)	
The	antioxidants,	enhanced	Cd‐induced	testicular	
injury.	
[96]	
Monensin	 p.o.	 14	mg/kg,	applied	after	Cd‐
intoxication	
Mice,	exposed	to	subacute	
intoxication	with	Cd(II)	
acetate	for	2	weeks	(10	
mg/kg	b.w.)	
Monensin	reduces	Cd	concentration	in	the	testes	
by	50	%	compared	to	the	normal	control	and	
recovers	the	histology	of	the	testes	to	a	great	
extent.	
[97]
Abbreviations:	 Diethyldithiocarbamate	 (DED),	 N‐benzyl‐D‐glucamine	 dithiocarbamate	 (BGD),	 N‐p‐isopropylbenzyl‐D‐glucamine	 dithiocarbamate	 (PBGD);	
Disulfiram	(DSF);	Diphenyl	diselenide	(PhSe)2.	
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Table	10.	Antioxidants	and	chelating	agents,	tested	on	animal	model	to	reduce	Cd‐induced	cardiac	impairment.	
Compound	 Route	of	
administration	
Dose	 Animal	model Effect Ref.
DMPS	 i.v.	 n.a.	 Rabbits,	intoxicated	with	
Cd(II)	chloride	50	mg/kg	
b.w./week	for	10	weeks	
The	chelating	agent	decreases	Ca	and	Mg	
concentration	in	the	cardiac	muscle.	
[105]	
Caffeic	acid	
phenyl	ester	
i.p.	 10	μmol/kg	b.w.,	for	15	days	
along	with	Cd	
Rats,	intoxicated	with	
Cd(II)	chloride	1	
mg/kg/day	for	15	days	
(i.p.)	
The	antioxidant	decreases	MDA	level	in	the	
cardiac	muscle	in	the	Cd‐treated	rats;	increases	
NO	in	the	serum	and	inhibits	Cd‐induced	
myocardial	hypertrophy.	
[100]
Vitamin	E	and	
coenzyme	Q	
(10)	
i.m.	 Vitamin	E	‐	20	IU/kg/b.w.
Q10	‐	20	mg/kg	b.w.	
concurrent	with	Cd	
Rats,	exposed	to	0.4	
mg/kg	Cd	(i.p.)	
The	combination	of	both	oxidants	diminishes	the	
toxic	effects	induced	by	Cd.	
[101]
Taurine	
Vitamin	C	
p.o.	 100	mg/kg	b.w.	for	5	days,	
prior	to	Cd‐intoxication	
Mice,	received	Cd(II)	
chloride	for	6	days	(4	
mg/kg	b.w.)	
Both	antioxidants	decrease	Cd	concentration	in	
the	cardiac	muscle,	improve	antioxidant	defence	
system	and	preserve	the	normal	histoarchitecture	
of	the	heart.	
[103]	
Diethyl	
carbamate	
Data	not	
available	
Data	not	available	 Rats,	exposed	to	20	mg/kg	
b.w.	Cd	or	40	mg/kg	b.w.	
Cd/	daily	for	60	days	
The	chelating	agent	reduces	Cd	concentration	by	
36%	compared	to	the	control	and	recovers	Fe	
homeostasis.	
[69]
DMSA	 Intragastrically	 25	mg/kg	
50	mg/kg	for	5	days	after	Cd‐
intoxication	
Mice,	treated	with	100	
mg/L	for	8	weeks	
DMSA	reduces	the	concentration	of	Cd	in	blood,	
heart,	liver	and	kidneys,	improves	blood	pressure	
and	antioxidant	defence	system	in	the	heart.	
[104]
α‐Lipoic	acid	
(ALA)	
melathonin	
Information	not	
found	
ALA	‐	25	mg/kg	b.w.	/day;	
Melathonin	‐	10	mg/kg	
b.w./day,	
applied	together	with	Cd(II)	
Rats,	subjected	to	
subchronic	Cd	intoxication	
5	mg/kg	b.w.	/day	for	15	
days	
The	combination	of	both	agents	inhibits	Cd‐
induced	cardiac	impairment.	
[102]	
Monensin	 p.o.	 14	mg/kg	after	Cd	intoxication	
for	2	weeks	
Mice,	exposed	to	10	
mg/kg	daily	Cd(II)	acetate	
for	2	weeks	
Monensin	reduces	Cd	concentration	in	the	heart	
by	90%	compared	to	the	control	and	recovers	the	
morphology	of	the	heart.	
[47]
	
	
	
Our	 results	have	demonstrated	 that	monensin	 (applied	 as	
tetraethylammonium	 salt)	 reduces	 Cd	 concentration	 in	 the	
testes	of	Cd‐treated	mice	by	50	%	compared	to	the	control.	The	
administration	of	the	chelating	agent	to	the	Cd‐intoxicated	mice	
restored	 the	histology	of	 the	 testes	 to	normal	 to	a	great	exent	
[97].	
	
5.	Antioxidants	and	chelating	agents,	tested	to	inhibit	Cd‐
induced	cardiac	impairment	
	
Cd	 is	 a	 vascular	 toxicant	 that	 induces	 hypertension	 and	
myocardial	 hypertrophy.	 The	 generation	 of	 ROS	 either	 by	
affecting	Fe	homeostasis	or	NO	level	in	the	endothelial	cells	has	
been	 considered	 as	 a	 primary	 mechanism	 for	 Cd‐induced	
cardiac	toxicity.		
Cd	 induces	expression	of	stress	genes	which	 in	turn	alters	
the	activity	of	the	antioxidant	enzymes	[100].	The	antioxidants	
and	chelating	agents,	screened	on	animal	models	to	prevent	Cd‐
induced	cardiac	toxicity,	are	summarized	in	Table	10.	
The	 combination	 of	 coenzyme	 Q(10)	 and	 Vitamin	 E	 has	
been	 demonstrated	 to	 reverse	 Cd‐induced	 alterations	 in	 the	
antioxidant	 defense	 system	 of	 heart	 of	 rats,	 exposed	 to	 acute	
Cd‐intoxication	[101].	
Caffeic	acid	phenyl	ester	(CAPE)	administrated	concurrent	
with	Cd	prevents	the	morphological	alterations,	induced	by	Cd	
in	the	heart	of	Cd‐treated	rats	by	decreasing	lipid	peroxidation	
and	improving	NO	homeostasis	[100].	
The	 combination	 of	 α‐lipoic	 acid	 and	 melatonin	 applied	
along	with	 the	 Cd	 treatment	 also	 inhibits	 Cd‐induced	 cardiac	
impairment	 in	 rats,	 subjected	 to	 subchronic	 Cd‐intoxication	
[102].	
Vitamin	 C	 and	 taurine,	 applied	 before	 Cd‐intoxication,	
decrease	 Cd	 accumulation	 in	 the	 heart	 of	 mice,	 exposed	 to	
subacute	 Cd‐intoxication.	 Vitamin	 C	 is	 more	 effective	 than	
taurine	 in	 preventing	 the	 activity	 of	 the	 antioxidant	 enzymes	
and	the	level	of	GSH	in	the	cardiac	muscle.	The	cardioprotective	
effect	of	both	antioxidants	is	substantiated	by	the	reduction	of	
Cd‐induced	pathological	changes	in	the	cardiac	tissue	[103].		
Among	 the	chelating	agents,	DMSA	and	monensin	seem	 to	
be	 the	 most	 effective	 in	 decreasing	 Cd	 concentration	 in	 the	
heart	of	animals,	intoxicated	with	Cd	[47,104].		
	
2,3‐Dimercapto‐1‐propanesulphonate	 (DMPS)	 also	
decreases	Cd	concentration	in	the	cardiac	muscle	of	Cd‐treated	
animals.	 However,	 precautions	 should	 be	 taken	 in	 its	
application	in	patients	with	cardiotoxicity	because	of	 its	affect	
on	the	Ca	and	Mg	concentration	in	the	heart	[105].	
	
6.	Conclusion	
	
There	are	many	published	reviews	on	chelating	agents	and	
antioxidants	tested	for	the	treatment	of	intoxications	with	toxic	
metal	 ions.	 To	 the	best	 of	 our	 knowledge	 however	 this	 is	 the	
first	 review	 that	 summarizes	 the	 literature	 information	
published	in	the	last	20	years	for	the	antioxidants	and	chelating	
agents,	 tested	 on	 animal	 models	 for	 the	 treatment	 of	 Cd‐
induced	organ	toxicity.	Detailed	information	regarding	the	Cd‐
induced	 pathological	 conditions	 (hepatotoxicity,	 renal	
dysfunction,	reproductive	disorder	and	cardiac	impairment)	 is	
also	presented.	The	data	discussed	 in	 the	review	demonstrate	
the	necessity	of	development	of	effective	scheme	for	therapy	of	
humans,	 exposed	 to	 Cd‐intoxication.	 Based	 on	 the	 data,	
presented	 in	 this	 paper,	 it	 could	 be	 concluded	 that	 the	
simultaneous	 application	 of	 antioxidants	 and	 chelating	 agents	
could	 be	 a	 good	 approach	 for	 the	 treatment	 of	 Cd‐induced	
organ	 toxicity.	 In	 order	 to	 identify	 the	 best	 antioxidant	 and	
chelating	 agent	 for	 the	 treatment	 of	 Cd‐induced	 pathological	
conditions,	detailed	studies	for	their	effects	on	different	organs	
in	animals,	exposed	to	Cd‐intoxications	are	needed.	
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